AstraZeneca Q3 2026 results, published on 30 October 2026, show total revenue of $46.9bn for the first nine months, up 7% at constant exchange rates (CER). Core earnings per share (EPS) reached $8.00, up 14%. The figures come from the company’s 9M and Q3 2026 results press release, which is intended for investor audiences and financial and business media.
Double-digit growth in Oncology, Respiratory & Immunology and Rare Disease drove the performance. That growth offset headwinds from loss of exclusivity for Farxiga and Brilinta and from volume-based procurement in China. Core operating profit was $16.4bn, also up 14% at CER.
Chief Executive Officer Pascal Soriot pointed to “strong commercial momentum” and said the company is on track for its 2030 ambition. He cited approvals for four new medicines and 12 positive Phase III programme readouts. AstraZeneca says these carry collective peak year revenue potential well in excess of ten billion dollars. The AstraZeneca Q3 2026 results also reconfirm full-year guidance.
AstraZeneca Q3 2026 Results: Revenue, Core EPS and Guidance in Detail
For the nine months, Total Revenue was $46,881m, up 8% at actual rates and 7% at CER. Product Revenue was $46,768m, made up of Product Sales of $43,962m and Alliance Revenue of $2,806m. Alliance Revenue rose 32% at CER. Collaboration Revenue added $113m.
The third quarter followed the same pattern. Q3 Total Revenue was $16,209m, up 7% at both actual rates and CER. Core EPS for the quarter was $2.79, up 19% at CER, and Reported EPS was $2.02, up 26% at CER. Nine-month Reported EPS was $5.62, up 11% at CER. The AstraZeneca Q3 2026 results therefore show earnings growing faster than revenue.
AstraZeneca reconfirmed its FY2026 guidance at CER. Total Revenue is expected to increase by a mid-to-high single-digit percentage and Core EPS by a low double-digit percentage. The Core tax rate is expected to fall between 18% and 22%. The company does not give guidance on a Reported basis because it cannot reliably forecast certain items, including fair value adjustments, impairment charges and legal settlement provisions.
AstraZeneca Revenue and EPS Summary (9M and Q3 2026)
| Metric | 9M 2026 ($m) | 9M % Change Actual | 9M % Change CER | Q3 2026 ($m) | Q3 % Change Actual | Q3 % Change CER |
|---|---|---|---|---|---|---|
| Product Sales | 43,962 | 7 | 5 | 15,066 | 5 | 5 |
| Alliance Revenue | 2,806 | 33 | 32 | 1,107 | 36 | 36 |
| Product Revenue | 46,768 | 8 | 6 | 16,173 | 7 | 7 |
| Collaboration Revenue | 113 | 22 | 23 | 36 | >3x | >3x |
| Total Revenue | 46,881 | 8 | 7 | 16,209 | 7 | 7 |
| Reported EPS ($) | 5.62 | 10 | 11 | 2.02 | 23 | 26 |
| Core EPS ($) | 8.00 | 14 | 14 | 2.79 | 17 | 19 |
Which Therapy Areas Drove AstraZeneca Q3 2026 Results?
Oncology was the largest contributor. Nine-month Oncology revenue was $21.9bn, up 16% at CER and equal to 47% of Total Revenue. The Oncology therapy area is the biggest part of the business. Its growth is a central reason the AstraZeneca Q3 2026 results beat the pace of other segments.
BioPharmaceuticals generated $16.7bn, or 36% of revenue, and declined 5% at CER. Within it, Respiratory & Immunology grew 10% to $7,268m. Cardiovascular, Renal & Metabolism (CVRM) fell 14% to $8,728m. Infectious Disease fell 12% to $735m. The press release does not provide product-level sales breakdowns, so these figures are not disclosed here.
Rare Disease delivered $7.5bn, up 11% at CER, or 16% of revenue. Other Medicines contributed $717m, down 8% at CER, or 2% of revenue. Taken together, the three main therapy areas account for 99% of the nine-month total when rounded, while Other Medicines accounts for the remainder.
AstraZeneca 9M 2026 Total Revenue by Therapy Area
| Therapy Area | 9M 2026 Revenue ($m) | % of Total Revenue | % Change CER |
|---|---|---|---|
| Oncology | 21,889 | 47 | 16 |
| BioPharmaceuticals | 16,731 | 36 | (5) |
| – Cardiovascular, Renal & Metabolism | 8,728 | 19 | (14) |
| – Respiratory & Immunology | 7,268 | 16 | 10 |
| – Infectious Disease | 735 | 2 | (12) |
| Rare Disease | 7,544 | 16 | 11 |
| Other Medicines | 717 | 2 | (8) |
Pipeline Momentum in AstraZeneca Q3 2026 Results: Approvals and Phase III Readouts
AstraZeneca recorded 47 approvals in major regions since its Q4 2025 results. These include first approvals for four new medicines: Etcamah, Baxfendy, Klygefa and Amlypave. The release does not state the indications or regions for these medicines, so those details are not disclosed here. Readers can check the clinical trials appendix for trial-level data.
The company also reported first Phase III data for three new molecular entities (NMEs): tozorakimab, efzimfotase alfa and sonesitatug vedotin. Year to date, it counts 12 positive Phase III programme readouts. Soriot said the series of upcoming 2027 readouts has potential of more than twenty billion dollars. That statement is forward-looking and depends on trial outcomes.
On pipeline scale, AstraZeneca reports 180 projects, including 116 NMEs or major life-cycle management projects in Phase II or Phase III. It has delivered 14 NMEs against a target of 20 by 2030 and has 20 NMEs in its late-stage pipeline, with two under review. The full AstraZeneca pipeline is available on the company site, and these numbers add context to the AstraZeneca Q3 2026 results.
AstraZeneca Pipeline Metrics Reported with 9M and Q3 2026 Results
| Pipeline Metric | Reported Figure |
|---|---|
| Projects in pipeline | 180 |
| NMEs or major life-cycle management in Phase II or Phase III | 116 |
| NMEs delivered against target of 20 by 2030 | 14 |
| NMEs in late-stage pipeline | 20 |
| NMEs under review | 2 |
| Approvals in major regions since Q4 2025 results | 47 |
| Positive Phase III programme readouts (year to date) | 12 |
New Medicines and Phase III NMEs Named in the Release
| Item | Type | Details Disclosed in Release |
|---|---|---|
| Etcamah | First approval, new medicine | Indication not disclosed |
| Baxfendy | First approval, new medicine | Indication not disclosed |
| Klygefa | First approval, new medicine | Indication not disclosed |
| Amlypave | First approval, new medicine | Indication not disclosed |
| Tozorakimab | NME, first Phase III data | Trial results not disclosed |
| Efzimfotase alfa | NME, first Phase III data | Trial results not disclosed |
| Sonesitatug vedotin | NME, first Phase III data | Trial results not disclosed |
